Social network
  • Visit We R Hope page

    We R Hope by Sanofi

  • Fighting dengue ferver

    Fighting dengue ferver

  • Meet Anne-Olivier Bandini: R&D Team Leader, France

  • Isabelle, Type 1 diabetes, France

    Isabelle, Type 1 diabetes, France

    Tools content (print, share, increase/decrease text size):


      R&D Portfolio

      At the beginning of February 2017, the R&D pipeline contained 44 pharmaceutical new molecular entities (excluding Life Cycle Management) and vaccine candidates in clinical development of which 13 are in Phase III or have been submitted to the regulatory authorities for approval.


      © Sanofi 2004-2017 - All rights reserved - Update: February 08, 2017

      • Site complies with W3C WCAG 2.0 (new window, in english)